Ts2 mice, a DS mouse model that develops adult-onset Rab5+ endosomal pathology and cholinergic degeneration in the basal forebrain18, and control 2 N (wildtype) mice were treated at approximately six months of age with either neflamapimod (3 mg/kg body weight) or vehicle (1% Pluronic F108), twice daily (BID) by oral gavage, for 28 days. Here, RAB5A is linked to Dravet syndrome.